NOTICE TO THE MARKET

BIOTOSCANA INVESTMENTS S.A. (“Company” or “GBT”) (B3: GBIO33), a leading biopharmaceutical company in Latin America, announces to its shareholders and the market in general that it has entered into an exclusive licensing agreement with Eisai Inc., the U.S. pharmaceutical subsidiary of Tokyo, Japan-based Eisai Co., Ltd., to commercialize HALAVEN^® (eribulin mesylate), LENVIMA^® (lenvatinib), FYCOMPA^® (perampanel) and INOVELON^® (rufinamide) throughout Latin America, including Brazil, Argentina and Mexico.

Under the new agreement, GBT will be responsible for marketing authorizations, market access, commercialization, distribution throughout Latin America, however, Eisai will retain the rights to Halaven and Lenvima in Mexico.

Montevideo, October 3, 2017

BIOTOSCANA INVESTMENTS S.A.
Claudio Coracini
Legal representative in Brazil

To access the notice to the market in PDF format, click here.

Updated on 01/02/2019 at 04:56 pm